Bernhardt MB, Hicks MJ, Pappo AS
Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma. [JOURNAL ARTICLE]
Pediatr Blood Cancer 2009 Sep 3.
Malignant melanoma is rare in pediatrics, and therapies for patients with disseminated disease have not been well studied. This report describes our experience with the use of high-dose interleukin 2 (aldesleukin, IL-2) in a 2-year-old child with metastatic melanoma and describes our approach for the administration of this agent to young patients. Pediatr Blood Cancer (c) 2009 Wiley-Liss, Inc.
More from this journal |
